Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for crohn's disease

Katsuyoshi Matsuoka, Takanori Kanai

研究成果: Review article

8 引用 (Scopus)

抜粋

It is not too much to say that infliximab has revolutionized the treatment of Crohn's disease. However, there is the problem of 'secondary failure' wherein the effect may diminish during treatment. This is a much-discussed topic. For example, not all patients with secondary failure can maintain remission with dose intensification to 10 mg/kg. It is also important to make the appropriate drug selection and to clarify the optimal timing of dose intensification for achieving long-term maintenance of remission, including discussion of the first priority use of adalimumab.

元の言語English
ページ(範囲)17-19
ページ数3
ジャーナルDigestion
88
発行部数1
DOI
出版物ステータスPublished - 2013 1 1

ASJC Scopus subject areas

  • Gastroenterology

フィンガープリント Mechanism and therapeutic strategy of secondary failure to anti-tumor necrosis factor-α monoclonal antibody treatment for crohn's disease' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用